66th ASH Annual Meeting: 622. Lymphomas: Translational – Non-Genetic: New Approaches and Models for Improving Lymphoma Therapies

Symposia: Lymphomas: Translational – Non-Genetic Oral and Poster Abstracts
Oral

Research, Fundamental Science, Combination therapy, Translational Research, Non-Hodgkin lymphoma, Lymphomas, Clinical Practice (Health Services and Quality), Elderly, B Cell lymphoma, T Cell lymphoma, Diseases, Immune mechanism, Indolent lymphoma, Treatment Considerations, Immunology, Lymphoid Malignancies, Biological Processes, Technology and Procedures, Molecular biology, Study Population, Human, Pathogenesis, Omics technologies

Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)

Moderators:

Maher K. Gandhi, PhD, FRACP, FRCPath, University of Queensland Diamantina Institute and Cynthia K. Hahn, MD, PhD, ARRAY(0xe16b238)

Disclosures:

No relevant conflicts of interest to declare.

This session will describe novel molecular pathways in lymphoma and how we might be able to target these with new agents or combinations of agents.

4:30 PM

973

Dual HDAC and EZH2 Inhibition Primes Mosunetuzumab for the Treatment of Germinal Center-Derived B-Cell Lymphoma

Ted B. Piorczynski, PhD¹, Saagar Jain²^*, Manuel Pazos II, MS, BS³^*, Yun Kyoung Tiger, MD, PhD⁴, Seda S. Tolu, MD⁵ and Jennifer E. Amengual, MD⁶

¹Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY
²Columbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York
³Columbia University Medical Center, NEW YORK, NY
⁴Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
⁵Division of Hematology & Oncology, Columbia University Irving Medical Center, New York City, NY
⁶Division of Hematology & Oncology, Columbia University Irving Medical Center, New York

4:45 PM

974

A Murine Phase 2 Proof-of-Concept Study of Polatuzumab Vedotin in Combination with Venetoclax in Experimental Therapy of BCL2-Positive Aggressive Lymphomas

Dmitry Kazantsev, MSc, PhD¹^*, Eva Pokorna, Ing, CSc²^*, Kristýna Nožičková, MD³^*, Alexandra Dolníková, MSc²^*, Nicol Renešová, MSc²^*, Liliana Tuskova, MD¹^*, Marek Trněný, MD, CSc^4,5 and Pavel Klener^6,7^*

¹Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
²Institute of Pathological Physiology, Charles University, First Faculty of Medicine, Prague, Czech Republic
³First Faculty of Medicine, Institute of Pathological Physiology, Charles University, Prague, Czech Republic
⁴Charles University, First Faculty of Medicine, Prague, Czech Republic
⁵First Dept. of Internal Medicine- Hematology, University General Hospital, Prague, Czech Republic
⁶1st Department of Medicine – Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
⁷Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Praha 2, Czech Republic

5:00 PM

975

Structural and Functional Analysis of the Clonotypic B Cell Receptor Immunoglobulin in Splenic Marginal Zone Lymphoma: Ontogenetic and Therapeutic Implications

Anastasia Iatrou^1,2^*, Marco Patrone³^*, Ioannis Sarrigeorgiou⁴^*, Nikolaos Pechlivanis²^*, David Graham Oscier⁵, Alexandra Traverse-Glehen, MD, PhD⁶^*, Raphael Sandaltzopoulos¹^*, Niki Stavroyianni⁷^*, Andreas Agathangelidis⁸^*, Georgios Petrakis⁹^*, Triantafyllia Koletsa⁹^*, Peggy Lymberi⁴^*, Paolo Ghia^10,11, Anastasia Chatzidimitriou^2,12^*, Massimo Degano³^* and Kostas Stamatopoulos^2,12^*

¹Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece
²Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece
³Università Vita-Salute San Raffaele and Biocrystallography Group, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy
⁴Immunology Laboratory, Immunology Department, Hellenic Pasteur Institute, Athens, Greece
⁵Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom
⁶Service de Pathologie Sud, Hospices Civils de Lyon, Pierre-Bénite, France
⁷Department of Hematology - BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
⁸School of Biology, National and Kapodistrian University of Athens, Athens, Greece
⁹Pathology Department, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
¹⁰Division of Experimental Oncology, B cell neoplasia, IRCCS Ospedale San Raffaele, Milan, Italy
¹¹Medical School, Università Vita-Salute San Raffaele, Milano, Italy
¹²Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden

5:15 PM

976

Metabolic Determinants of Ferroptosis in B-Cell Lymphoma

Etienne Leveille, MD¹^*, Eden Bramson¹^*, Mark E Robinson, PhD¹^*, Thierry Bertomeu, PhD²^*, Andrew Chatr-Aryamontri, PhD²^*, Shalin Kothari, MD¹^* and Markus Müschen, MD¹

¹Center of Molecular and Cellular Oncology, Yale University, New Haven, CT
²The ChemoGenix pooled CRISPR screening platform of the Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, Canada

5:30 PM

977

Faecalibacterium Prausnitzii Confers a Protective Effect Against the Development of NKTCL

Zhuangzhuang Shi, PhD¹^*, Wenxing Jiang²^*, Zhaoming Li²^*, Wei-Hua Chen³^* and Mingzhi Zhang, MD²

¹Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
²The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
³College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China

5:45 PM

978

Toll-like Receptor 7/8 Pathway Is a Therapeutic Target in Primary CNS Lymphoma

Michael P Randall, MD¹, Huimin Geng, PhD²^*, Lingjing Chen, PhD¹^*, Aishwarya Ballapuram³^*, Chitoh Yung¹^*, Ming Lu¹^*, Gregory Chin⁴^*, Michael Mish, PhD⁴^*, Jamie Bates, PhD⁴^* and James L. Rubenstein, MD, PhD⁵

¹Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA
²Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA
³University of California, San Francisco, San Francisco, CA
⁴Oncology Sciences, Gilead, Foster City, CA
⁵Hematology/Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

622.O3.6 622. Lymphomas: Translational – Non-Genetic: New Approaches and Models for Improving Lymphoma Therapies